Study
Rapamycin Exerts Its Geroprotective Effects in the Ageing Human Immune System by Enhancing Resilience Against DNA Damage
Low-dose rapamycin enhanced DNA damage resilience in aging human immune cells, providing a mechanism for its geroprotective effects.
Summary Can low-dose rapamycin help older immune cells resist age-related damage? Show / hide ↓
Researchers gave low-dose rapamycin or a placebo to older adults and studied their immune cells. They also tested human T cells, a type of immune cell, in the laboratory after exposing them to DNA damage. Rapamycin blocked some effects of mTOR, a cell-growth control system, and reduced senescence, a state where cells stop working properly but remain alive. The treated cells handled DNA damage better, but the study did not show that rapamycin extends life or prevents illness in people.
What this means for you: This is early laboratory and experimental evidence, not a reason to buy or self-use rapamycin. The number of participants was not reported, and the findings do not establish benefits or safety for healthy adults.
early evidenceThis study investigated how rapamycin affects the aging human immune system using a placebo-controlled experimental medicine design in older adults supplemented with low-dose rapamycin, plus ex vivo experiments on human T cells exposed to acute genotoxic stress. The researchers found that rapamycin and other mTOR inhibitors suppressed senescence in human T cells, but this did not occur by slowing protein synthesis or halting cell division. Instead, rapamycin enhanced resilience against DNA damage in aged immune cells. The study positions mTOR inhibitors as senomorphic agents that mitigate cellular senescence rather than killing senescent cells (senolytic). This is one of the few studies examining rapamycin's effects directly on the human immune system rather than in mice or cell lines. Sample size was not stated in the abstract.
Rapamycin exerts geroprotective effects in the ageing human immune system by enhancing resilience against DNA damage.
Sample size not clearly stated in the abstract. The study used non-immunosuppressive doses, so results may not apply to typical rapamycin dosing protocols. Ex vivo experiments may not fully replicate in vivo conditions.
Cited by
1 encyclopedia entries reference this study.